TLR3 and melanoma: Ongoing trials investigate the application of TLR3 agonists in other malignancies, among others, in advanced colorectal cancer in combination with pembrolizumab (NCT04119830), in malignant melanoma (NCT04093323) and in the neoadjuvant setting in malignant pleural mesothelioma (NCT04345705) (176).